ASTRUM-006 provides phase 3 evidence that perioperative immune checkpoint inhibition improves event-free survival with Asian SOX-based chemotherapy in PD-L1-positive gastric cancer. Its postoperative chemotherapy-sparing strategy is attractive, although unmasking, event adjudication, and non-R0 or occult metastatic dis...
Hyung-Don Kim, I. Chau, R. Sundar· i Medicina· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies, characterised by rising incidence, poor long-term survival, and profound resistance to systemic therapy. Its poor prognosis reflects late diagnosis, early metastatic spread, and a uniquely desmoplastic, immunosuppressive tumour microe...
A. Lefas, H. Lote, I. Chau· Precision Oncology· 0 citations
BACKGROUND
Nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit compared with chemotherapy for patients with previously untreated advanced esophageal squamous cell carcinoma (ESCC). We report OS and additional analyses at a minimum follow-up of 5 years....
K. Kato, J. Ajani, Y. Doki et al.· Annals of Oncology· 2 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
